ST交昂(600530) - 2021 Q4 - 年度财报

Financial Performance - In 2021, the company's operating revenue was CNY 362,576,663.60, an increase of 8.98% compared to CNY 332,695,487.68 in 2020[21] - The net profit attributable to shareholders of the listed company for 2021 was CNY 37,177,627.01, a decrease of 59.88% from CNY 92,670,121.92 in 2020[21] - The net profit after deducting non-recurring gains and losses was CNY 25,330,968.24, representing a significant increase of 258.85% compared to CNY 7,058,882.62 in 2020[21] - The cash flow from operating activities for 2021 was CNY 104,062,540.92, up 54.90% from CNY 67,178,715.33 in 2020[21] - The total revenue for the year 2021 was 363 million RMB, representing a year-on-year increase of 8.98%[45] - The net profit attributable to shareholders was 37 million RMB, a significant decrease of 59.88% compared to the previous year, primarily due to the sale of a subsidiary[45] Assets and Liabilities - As of the end of 2021, the total assets amounted to CNY 1,352,345,202.99, an increase of 4.51% from CNY 1,293,961,078.31 at the end of 2020[21] - The net assets attributable to shareholders of the listed company were CNY 875,850,649.00, reflecting a 4.90% increase from CNY 834,900,061.69 in 2020[21] - Cash and cash equivalents increased by 38.49% to 163.43 million yuan, accounting for 12.08% of total assets[61] - Inventory rose by 29.57% to 55.67 million yuan, representing 4.12% of total assets[61] - Long-term equity investments decreased by 59.23% to 27.71 million yuan, accounting for 2.05% of total assets[61] - Short-term borrowings decreased by 37.50% to 50 million yuan, representing 3.70% of total liabilities[61] Profitability and Margins - Basic earnings per share for 2021 were CNY 0.05, down 57.98% from CNY 0.119 in 2020[22] - The weighted average return on equity decreased by 7.04 percentage points to 4.17% in 2021[23] - The company achieved a gross profit margin of 43.0% in its main business operations, indicating stable profitability[50] - The gross profit margin for the overall business was 42.83%, reflecting an increase of 2.29 percentage points from the previous year[51] - The gross profit margin for the health products segment was 58.67%, which increased by 13.23 percentage points[54] Business Segments and Growth - The company achieved a turnaround in the health product segment, marking its first profit in nearly seven years[29] - The raw material business saw significant growth, particularly in exports, due to enhanced R&D efforts and improved production management[29] - The healthcare segment reported a revenue of CNY 159,768,650.32, with a year-on-year growth of 37.49%[51] - The company operates six self-managed profit-oriented elderly medical care institutions, providing services such as medical care, rehabilitation, nursing, and health management[40] - The company’s health supplement products include probiotics and herbal extracts, targeting various health needs such as immune enhancement and blood lipid regulation[36] Research and Development - The company's R&D expenses increased by 22.65% to 15.64 million RMB, reflecting a commitment to technological innovation[47] - The company holds 18 Chinese invention patents, including 11 related to probiotics, showcasing its strong technological capabilities[42] - The company has completed the technical development of high-activity probiotic raw materials for dairy products, improving production efficiency and reducing costs by over 30%[70] - The company has made significant investments in research and development, focusing on products that align with market trends and consumer health needs[69] Market Trends and Opportunities - The health supplement industry in China reached a sales figure of 198.4 billion yuan in 2020, showing a year-on-year growth of 11.52%[33] - The projected market size of the health supplement industry is expected to reach approximately 517.8 billion yuan by 2026, maintaining a growth rate of at least 4% over the next five years[33] - The company aims to expand its probiotic product line and enhance its competitive edge through differentiated strategies[87] - The company is focusing on mid-range elderly medical care institutions and deepening its presence in the Yangtze River Delta region[87] Corporate Governance and Compliance - The company has received a standard unqualified audit opinion from Da Xin Accounting Firm[4] - The company maintains independence from its controlling shareholder in terms of assets, personnel, and financial management[101] - The company has established an independent financial accounting department with dedicated personnel and a standardized financial management system[102] - The company has established a performance evaluation system linking executive compensation to business performance[99] Social Responsibility and Environmental Initiatives - The company actively participates in social responsibility initiatives, including health education programs and community support[144] - The company has invested in upgrading wastewater treatment facilities to enhance environmental protection efforts[145] - The company implemented a central air conditioning cooling water system renovation project, expected to save approximately 150 tons of standard coal annually[142] Challenges and Risks - The company faced significant impacts on operations and business due to the COVID-19 pandemic, affecting the opening and occupancy rates of its facilities[151] - The company is exposed to risks from policy changes affecting healthcare payments and rising labor costs in the medical care sector[93] - The healthcare food industry faces increasing regulatory scrutiny, necessitating compliance with new laws and internal management standards[92]